- API
Cumulative Influenza Vaccination Coverage, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years
data.cdc.gov | Last Updated 2024-05-03T13:59:26.000ZCumulative Influenza Vaccination Coverage, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years • These monthly flu vaccination coverage estimates for pregnant persons are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between CDC’s Immunization Safety Office and nine integrated health care organizations.§ This system has been used annually to estimate vaccination coverage among pregnant persons. COVID-19 vaccination coverage for pregnant persons is available here. • Figure 3A. Monthly Cumulative Influenza Vaccination Coverage*, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years, United States, Data Source: Vaccine Safety Datalink • Figure 3B. Cumulative Influenza Vaccination Coverage*, by Month, Flu Season, and Race/Ethnicity, Pregnant Persons 18-49 years, United States, Data Source: Vaccine Safety Datalink • For any month’s coverage estimate, the denominator is the number of persons with a pregnancy during the current flu season (defined as August through March) beginning before or during the specified month. The numerator is the subset of the denominator who have received flu vaccination prior to, during, or after pregnancy. The denominator increases as more persons are identified as pregnant or having been pregnant during the flu season. Cumulative vaccination coverage for one month may be lower than cumulative coverage for a previous month due to addition to the denominator of persons who are less likely to have received vaccination.
- API
Vaccine Hesitancy for COVID-19: County and local estimates
data.cdc.gov | Last Updated 2021-06-17T20:27:47.000ZDue to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy. To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates (https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data. We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS) (https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates at the Public Use Microdata Areas (PUMA) level using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center(https://mcdc.missouri.edu/applications/geocorr2014.html). PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations. The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31.. PUMA COVID-19 Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-Public-Use-Microdat/djj9-kh3p
- API
NNDSS - TABLE 1MM. Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus to Guanarito virus
data.cdc.gov | Last Updated 2022-01-12T18:39:21.000ZNNDSS - TABLE 1MM. Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus to Guanarito virus – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). § Prior to 2015, CDC's National Notifiable Diseases Surveillance System (NNDSS) did not receive electronic data about incident cases of specific viral hemorrhagic fevers; instead data were collected in aggregate as "viral hemorrhagic fevers". NNDSS was updated beginning in 2015 to receive data for each of the viral hemorrhagic fevers listed.
- API
NNDSS - Table II. Giardiasis to Haemophilus influenza
data.cdc.gov | Last Updated 2016-03-03T19:42:32.000ZNNDSS - Table II. Giardiasis to Haemophilus influenza - 2014. In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (≥ 1,000 and ≤ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Data for H. influenzae (age <5 yrs serotype b, nonserotype b, and unknown serotype) are available in Table I. More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.
- API
HHS Provider Relief Fund
data.cdc.gov | Last Updated 2024-10-09T23:41:06.000ZHHS is providing support to healthcare providers fighting the coronavirus disease 2019 (COVID-19) pandemic through the bipartisan Coronavirus Aid, Relief, & Economic Security (CARES) Act; the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act, which provide a total of $178 billion for relief funds to hospitals and other healthcare providers on the front lines of the COVID-19 response. This funding supports healthcare-related expenses or lost revenue attributable to COVID-19 and ensures uninsured Americans can get treatment for COVID-19. HHS is distributing this Provider Relief Fund (PRF) money and these payments do not need to be repaid. The Department allocated $50 billion in PRF payments for general distribution to Medicare facilities and providers impacted by COVID-19, based on eligible providers' net reimbursement. HHS has made other PRF distributions to a wide array of health care providers and more information on those distributions can be found here: https://www.hhs.gov/coronavirus/cares-act-provider-relief-fund/data/index.html
- API
COVID-19 County Hesitancy
data.cdc.gov | Last Updated 2021-06-17T20:00:41.000ZThis map shows estimates of COVID-19 vaccine hesitancy rates using data from the U.S. Census Bureau’s Household Pulse Survey (HPS). We estimate hesitancy rates in two steps. First, we estimate hesitancy rates at the state level using the HPS for the collection period March 3, 2021 – March 15, 2021, which is referred to as Week 26. Then, we utilize the estimated values to predict hesitancy rates in more granular areas using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center. PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations. We use the HPS survey question, “Once a vaccine to prevent COVID-19 is available to you, would you…get a vaccine?”, which provides the following options: 1) “definitely get a vaccine”; 2) “probably get a vaccine”; 3) “probably not get a vaccine”; 4) “definitely not get a vaccine”. COVID-19 vaccine hesitancy was defined as follows: hesitancy: includes survey responses indicating that they would “probably not” or “definitely not” receive a COVID-19 vaccine when available. strong hesitancy: include only survey responses indicating that they would “definitely not” receive a COVID-19 vaccine when available. Full methodology for estimates of COVID-19 vaccine hesitancy is available here. Demographic data were obtained from the 2019 American Community Survey (ACS) 5-year estimates. Overall social vulnerability index was obtained from the 2018 CDC Social Vulnerability Index. The CDC's Social Vulnerability Index (SVI) summarizes the extent to which a community is socially vulnerable to disaster. The factors considered in developing the SVI include economic data as well as data regarding education, family characteristics, housing language ability, ethnicity, and vehicle access. SVI values range from 0 (least vulnerable) to 1 (most vulnerable). The SVI can also be categorized as follows: Very Low (0.0-0.19), Low (0.20-0.39); Moderate (0.40-0.59); High (0.60-0.79); Very High (0.80-1.0). The ability to handle a COVID-19 outbreak was obtained from the Surgo Covid-19 Vaccine Coverage Index (CVAC). The Covid-19 Vaccine Coverage (CVAC) Index measures how well a community may be able to handle the repercussions of a COVID-19 outbreak. CVAC is based on a community's access to health care, affordable housing, transportation, childcare, or safe and secure employment. CVAC Index values range from 0 (least vulnerable) to 1 (most vulnerable). The CVAC Index can also be categorized as follows: Very Low (0.0-0.19), Low (0.20-0.39); Moderate (0.40-0.59); High (0.60-0.79); Very High (0.80-1.0). The percent of adults (18+) in the population who are fully vaccinated was obtained from the CDC COVID-19 Data Tracker, Integrated County View as of March 30, 2021. Vaccination rate data may not be available for all states. Systematic missing data in some states may result in vaccination coverage by county appearing artificially low.
- API
AH Monthly Provisional Counts of Deaths for Select Causes of Death by Sex, Age, and Race and Hispanic Origin
data.cdc.gov | Last Updated 2022-04-01T21:33:55.000ZProvisional counts of deaths by the month the deaths occurred, by age group, sex, and race/ethnicity, for select underlying causes of death for 2020-2021. Final data are provided for 2019. The dataset also includes monthly provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.
- API
Early Model-based Provisional Estimates of Drug Overdose, Suicide, and Transportation-related Deaths
data.cdc.gov | Last Updated 2022-03-30T16:02:45.000ZThis dataset provides model-based provisional estimates of the weekly numbers of drug overdose, suicide, and transportation-related deaths using “nowcasting” methods to account for the normal lag between the occurrence and reporting of these deaths. Estimates less than 10 are suppressed. These early model-based provisional estimates were generated using a multi-stage hierarchical Bayesian modeling process to generate smoothed estimates of the weekly numbers of death, accounting for reporting lags. These estimates are based on several assumptions about how the reporting lags have changed in recent months across different jurisdictions, and the resulting estimates differ from other sources of provisional mortality data. For now, these estimates should be considered highly uncertain until further evaluations can be done to determine the validity of these assumptions about timeliness. The true patterns in reporting lags will not be known until data are finalized, typically 11–12 months after the end of the calendar year. Importantly, these estimates are not a replacement for monthly provisional drug overdose death counts, or quarterly provisional mortality estimates. For more detail about the nowcasting methods and models, see: Rossen LM, Hedegaard H, Warner M, Ahmad FB, Sutton PD. Early provisional estimates of drug overdose, suicide, and transportation-related deaths: Nowcasting methods to account for reporting lags. Vital Statistics Rapid Release; no 11. Hyattsville, MD: National Center for Health Statistics. February 2021. DOI: https://doi.org/10.15620/ cdc:101132
- API
NNDSS - TABLE 1BB. Q fever, Total to Q fever, Chronic
data.cdc.gov | Last Updated 2022-01-12T18:37:43.000ZNNDSS - TABLE 1BB. Q fever, Total to Q fever, Chronic - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S, a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
- API
NNDSS - TABLE 1DD. Rubella to Rubella, congenital syndrome
data.cdc.gov | Last Updated 2022-01-12T18:38:04.000ZNNDSS - TABLE 1DD. Rubella to Rubella, congenital syndrome - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).